Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study

The objective of this study was to evaluate the efficacy and safety profile of weekly docetaxel, estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer. Forty-eight patients received 35 mg m(−2) of weekly docetaxel for 3 out of every 4 weeks, 280 mg of estramustine t...

Full description

Saved in:

Bibliographic Details
Main Authors:	Carles, J, Font, A, Mellado, B, Domenech, M, Gallardo, E, González-Larriba, J L, Catalan, G, Alfaro, J, Gonzalez del Alba, A, Nogué, M, Lianes, P, Tello, J M
Format:	Artigo
Language:	Inglês
Published:	Nature Publishing Group 2007
Subjects:	Clinical Study
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2360463/ https://ncbi.nlm.nih.gov/pubmed/17955053 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604030
Tags:	Add Tag No Tags, Be the first to tag this record!

Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study

Similar Items